Thought this would be of interest to the group.
________________________________________________________________________
BIOSOURCE TECHNOLOGIES UNVEILS WEB SITE; SITE ENHANCES COMPANY'S GLOBAL
REACH AND INFORMATION DELIVERY CAPABILITIES
Biosource Technologies, Inc., an innovative healthcare and specialty
products biotechnology company, announced today that it has a connection
to the Internet with a home page on the World Wide Web. The site can be
accessed at http://www.biosource-bti.com.
Biosource web site visitors will find a profile of the company, and
detailed information about its products, executive management team, and
its proprietary GENEWARE(R) system. Additional pages provide information
about recent events and news, and patents and licenses.
"Our web site increases our global reach and allows us to instantaneously
deliver information to our many publics," said Robert L. Erwin, Biosource
chairman of the board and chief executive officer. "Our site will be a
valuable communication tool for those investors, potential business
partners, the media, and anyone else who needs relevant, useful, and
up-to-date information about our company," said Erwin.
Biosource Technologies is engaged in the development and commercialization
of new pharmaceutical and therapeutic products. A centerpiece of the
company's technology is its GENEWARE expression system, through which new
genes are introduced into normal growing plants to generate high-yield
production of biotechnology products. This transient system enables
normal-growing plants to produce high concentrations of complex
biochemicals without the time and expense required using transgenic
systems.
"We have developed a technology that could save lives and transform the
way we produce medicines, while also lowering the cost of producing
antibiotics and other useful products," said Erwin. "The Internet is a
medium to enlighten and educate a number of key groups and individuals
about the ground-breaking research and product development work we are
doing."
Founded in 1987, Biosource Technologies has 154 United States and foreign
patents pending or issued. Biosource's product-development efforts are
focused on unique antiinfectives, oncological compounds, and
immunologicals. In November 1995, the company announced plans to begin
large-scale production of genetically-engineered proteins grown in tobacco
plants.
For more information, contact Dick Shaner, Jr. of Crowley Webb Public
Relations, 716-856-2932
